Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250276 | 0.78 | ALDH1A1 (0.42) | TSHRMEN1KMT2A | |
| SCHEMBL6350737 | 0.74 | GAA (0.35) | TSHRMEN1GAACYP2C9CYP2C19 | |
| SCHEMBL5025958 | 0.71 | ALDH1A1 (0.59) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL5025960 | 0.71 | ALDH1A1 (0.59) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL9856479 | 0.70 | ALDH1A1 (0.34) | TSHRMEN1KMT2A | |
| SCHEMBL524900 | 0.65 | PPARD (0.58) | PPARDTSHR | |
| SCHEMBL491733 | 0.65 | PPARD (0.46) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL491525 | 0.65 | PPARD (0.50) | PPARDTSHRMEN1GAACYP2C9 | |
| SCHEMBL6350740 | 0.64 | MEN1 (0.31) | TSHRMEN1KMT2A | |
| SCHEMBL27819068 | 0.64 | PPARD (0.52) | PPARDTSHRMEN1GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |